QuidelOrtho misses Q1 revenue estimates, cuts FY outlook

Quidelortho

05/05/2026 21:47

Overview

US diagnostics provider's Q1 revenue fell 10.5% yr/yr, missing analyst expectations

Posts Q1 adjusted loss, missing analyst expectations

Company cut full-year 2026 revenue and adjusted EPS guidance

Outlook

QuidelOrtho sees 2026 revenue of $2.70-$2.75 bln, down from prior $2.7-$2.9 bln range

Company expects 2026 adjusted EBITDA of $615-$630 mln, revised from previous $630-$670 mln

Company says guidance reflects uncertainty over China NHSA IVD pricing guidelines

Result Drivers

WEAK RESPIRATORY SEASON - Co said Point of Care revenue fell 34% due to a significantly weaker respiratory season versus Q1 2025

CHINA AND MIDDLE EAST DISRUPTION - Co said Labs revenue dropped 5% due to slower distributor sales in China, business disruption in the Middle East, and ending a joint business arrangement with Grifols

IMMUNOHEMATOLOGY GROWTH - Co said Immunohematology revenue grew 8%, mainly driven by growth in North America, China and JPAC

Company press release: ID:nPn2Nwd9Na

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$619.80 mln
$665.22 mln (7 Analysts)
Q1 Adjusted EPS
Miss
-$0.04
$0.40 (5 Analysts)
Q1 EPS
-$1.35
Q1 Net Income
-$91.80 mln
Q1 Basic EPS
-$1.35
Q1 Operating Income
-$31.80 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for QuidelOrtho Corp is $30.00, about 141.5% above its May 4 closing price of $12.42

The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)